2. Signaling Pathways
  3. Immunology/Inflammation
  4. NOD-like Receptor (NLR)
  5. NLRP3 Isoform
  6. NLRP3 Inhibitor

NLRP3 Inhibitor

NLRP3 Inhibitors (73):

Cat. No. Product Name Effect Purity
  • HY-117432
    JC-171
    		Inhibitor 98.41%
    JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC50 of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages.
  • HY-121988
    INF4E
    		Inhibitor 99.38%
    INF4E is a potent NLRP3 inflammasome inhibitor. INF4E inhibits caspase-1 and NLRP3 ATPase activities. INF4E shows protection against the IR-induced myocardial injury and dysfunction.
  • HY-156034
    JT001
    		Inhibitor
    JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis.
  • HY-161727
    P2Y14R antagonist 1
    		Inhibitor
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis.
  • HY-161297
    NT-0249
    		Inhibitor
    NT-0249 is an orally active NLRP3 inhibitor. NT-0249 has anti-inflammatory activity
  • HY-131040
    NLRP3-IN-NBC6
    		Inhibitor 99.40%
    NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs).
  • HY-150965
    NDT-30805
    		Inhibitor
    NDT-30805 is a selective NLRP3 inflammasome inhibitor. NDT-30805 is a triazolopyrimidinone derivative and inhibits IL-1β release in PBMCs with an IC50 of 0.013 μM. NDT-30805 can be used for the research of inflammation and innate immunity.
  • HY-163744
    NLRP3-IN-42
    		Inhibitor
    NLRP3-IN-42 (compound H28) is a potent NLRP3 inhibitor with an KD value of 1.15 µM. NLRP3-IN-42 decreases the LPS (HY-D1056) induced protein expression of cleaved-caspase-1 (p20). NLRP3-IN-42 selectively inhibits IL-1β release.
  • HY-146802
    NLRP3-IN-9
    		Inhibitor
    NLRP3-IN-9 is a potent NLRP3 inhibitor. NLRP3-IN-9 inhibits IL-1β release. NLRP3-IN-9 reduces inflammation and mechanical hyperalgesia. NLRP3-IN-9 has the potential for the research of gout.
  • HY-163695
    NLRP3-IN-41
    		Inhibitor
    NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research.
  • HY-168009
    NLRP3-IN-45
    		Inhibitor
    NLRP3-IN-45 (D6) is an inhibitor of NLRP3 inflammasome activation, inhibiting the activity of IL-1β (IC50=41.79 nM). NLRP3-IN-45 exerts its effects without affecting the initial stage of NLRP3 inflammasome activation. NLRP3-IN-45 specifically inhibits the activation of NLRP3 inflammasome in the LPS-induced acute lung injury (ALI) mouse model.
  • HY-169188
    NLRP3-IN-50
    		Inhibitor
    NLRP3-IN-50 (compound SN3-1) is a potential NLRP3 inhibitor with therapeutic potential for inflammatory diseases..
  • HY-172102
    NLRP3-IN-68
    		Inhibitor
    NLRP3-IN-68 (Compound 2d) is a 1,3,4-oxadiazole derivative. NLRP3-IN-68 has strong anti-inflammatory and antioxidant activities, which can inhibit inflammatory cytokines secretion, iNOS expression and NLRP3 inflammasome activation. NLRP3-IN-68 can be used in the research of anti-inflammatory drugs.
  • HY-159482
    SBN-284
    		Inhibitor
    SBN-284 (compound 3x) is a dual inhibitor of blood-brain permeable Cholinesterases and the NLRP3 inflammasome and is effective against EeAChE, hAChE and eqBChE, the IC50 values of are 0.37, 0.31, 0.29 μM respectively, and the EC50 of NLRP3 inflamm is 1 μM. SBN-284 can be used in Alzheimer's disease research.
  • HY-168264
    MC1
    		Inhibitor
    MC1 is a potent NLRP3 inhibitor with a KD value of 19.3 nM. MC1 shows no cytotoxicity. MC1 ameliorates cognitive deficits without eliciting adverse effects and shows an absence of hepatotoxicity. MC1 has the potential for the research of Alzheimer's disease (AD).
  • HY-149123
    NLRP3-IN-16
    		Inhibitor
    NLRP3-IN-16 is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-16 inhibits IL-1β release with an IC50 of 0.065 μM. NLRP3-IN-16 can be used for the research of inflammation.
  • HY-164853
    Kanglexin
    		Inhibitor
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.
  • HY-159898
    AChE/BChE-IN-23
    		Inhibitor
    AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model.
  • HY-168594
    α-Glucosidase/NLRP3-IN-1
    		Inhibitor
    α-Glucosidase/NLRP3-IN-1 (Compound 8) is a dual inhibitor of α-glucosidase and NLRP3, exhibiting an IC50 of 6.6 μM against α-glucosidase and inhibiting NLRP3 in multiple cell lines at a concentration of 100 μM. α-Glucosidase/NLRP3-IN-1 demonstrates neuroprotective and antidiabetic properties, and can be utilized in relevant research.
  • HY-145911
    NLRP3-IN-7
    		Inhibitor
    NLRP3-IN-7 (Compound 36) is a selective NLRP3 inflammasome inhibitor. NLRP3-IN-7 effectively blocks the assembly of the NLRP3 inflammasome.